AR112702A1 - Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn - Google Patents

Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn

Info

Publication number
AR112702A1
AR112702A1 ARP180102714A AR112702A1 AR 112702 A1 AR112702 A1 AR 112702A1 AR P180102714 A ARP180102714 A AR P180102714A AR 112702 A1 AR112702 A1 AR 112702A1
Authority
AR
Argentina
Prior art keywords
independently
lower alkyl
formula
fluoro
hcv rna
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Klaus G Klumpp
Mark Smith
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of AR112702A1 publication Critical patent/AR112702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ARP180102714 2017-09-21 2018-09-21 Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn AR112702A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762561237P 2017-09-21 2017-09-21

Publications (1)

Publication Number Publication Date
AR112702A1 true AR112702A1 (es) 2019-11-27

Family

ID=65810030

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102714 AR112702A1 (es) 2017-09-21 2018-09-21 Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn

Country Status (12)

Country Link
US (2) US10682369B2 (enExample)
EP (1) EP3684374B1 (enExample)
JP (1) JP7299897B2 (enExample)
KR (1) KR102735678B1 (enExample)
CN (1) CN111194217B (enExample)
AR (1) AR112702A1 (enExample)
AU (1) AU2018335411B2 (enExample)
CA (1) CA3075645A1 (enExample)
IL (1) IL273398B2 (enExample)
SG (1) SG11202002431SA (enExample)
TW (1) TWI860279B (enExample)
WO (1) WO2019060740A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
TWI860279B (zh) 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
EP3865535A1 (en) 2020-02-11 2021-08-18 Bosti Trading Ltd. New method of synthesis of chitosan derivatives and uses thereof
TW202144465A (zh) 2020-02-11 2021-12-01 瑞士商諾和席卓股份有限公司 合成聚葡萄胺糖衍生物之新方法及其用途
WO2022174179A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AR126678A1 (es) 2021-08-06 2023-11-01 Novochizol Sa Composiciones para el cuidado de las plantas y usos de las mismas
CN117835822A (zh) 2021-08-06 2024-04-05 诺和席卓股份有限公司 包含可溶性交联壳聚糖的复合凝胶、聚合物支架、聚集体和薄膜的制备及其用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
KR20010099623A (ko) 1998-08-21 2001-11-09 비로파마 인코포레이티드 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
EE200100492A (et) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated Ensüümi IMPDH inhibiitorid
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
JP2005515172A (ja) 2001-11-02 2005-05-26 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体
US20050009873A1 (en) 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172992A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的修饰的2′和3′－核苷前药
MXPA05008736A (es) * 2003-02-19 2005-10-05 Univ Yale Analogos de nucleosido antivirales y metodos para tratar infecciones virales, especialmente infecciones por vih.
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
BRPI0409680A (pt) 2003-04-25 2006-04-18 Gilead Sciences Inc análogos de fosfonato anti-cáncer
AU2004235848B2 (en) 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
KR100883703B1 (ko) 2003-05-30 2009-02-12 파마셋 인코포레이티드 변형 불소화 뉴클레오시드 유사체
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
UA84050C2 (en) 2004-01-30 2008-09-10 Медивир Аб Hcv ns-3-serine protease inhibitors
JP2008523098A (ja) 2004-12-10 2008-07-03 エモリー・ユニバーシテイ ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
CN101384609A (zh) * 2006-02-14 2009-03-11 默克公司 用于治疗rna依赖性rna病毒感染的氨基磷酸（核苷）（芳基）酯
WO2007095269A2 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
PH12013500033A1 (en) 2010-07-19 2017-07-26 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG188497A1 (en) 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
RU2640582C2 (ru) 2011-08-01 2018-01-10 Мбс Фарма, Инк. Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
EP2709613B2 (en) * 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
PL2794629T3 (pl) * 2011-12-20 2018-02-28 Riboscience Llc 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv
WO2013142159A1 (en) * 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
ES2865402T3 (es) * 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CN110156838A (zh) * 2013-05-14 2019-08-23 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
NZ714927A (en) * 2013-05-16 2020-09-25 Riboscience Llc 4’-fluoro-2’-methyl substituted nucleoside derivatives
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
JP2016519146A (ja) * 2013-05-16 2016-06-30 リボサイエンス・エルエルシー ４’−アジド，３’−デオキシ−３’−フルオロ置換ヌクレオシド誘導体
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
US20190046552A1 (en) * 2015-04-07 2019-02-14 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
MX2018014377A (es) * 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
TWI860279B (zh) 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物

Also Published As

Publication number Publication date
TWI860279B (zh) 2024-11-01
CN111194217A (zh) 2020-05-22
WO2019060740A1 (en) 2019-03-28
JP2020534374A (ja) 2020-11-26
US20190231804A1 (en) 2019-08-01
IL273398B1 (en) 2024-10-01
CA3075645A1 (en) 2019-03-28
SG11202002431SA (en) 2020-04-29
US20210046100A1 (en) 2021-02-18
US11351186B2 (en) 2022-06-07
JP7299897B2 (ja) 2023-06-28
CN111194217B (zh) 2024-01-12
IL273398A (en) 2020-05-31
IL273398B2 (en) 2025-02-01
AU2018335411A1 (en) 2020-03-26
US10682369B2 (en) 2020-06-16
TW201919649A (zh) 2019-06-01
EP3684374A4 (en) 2021-06-16
KR20200056420A (ko) 2020-05-22
EP3684374B1 (en) 2025-07-30
KR102735678B1 (ko) 2024-11-27
EP3684374A1 (en) 2020-07-29
AU2018335411B2 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
AR112702A1 (es) Derivados de nucleósidos sustituidos con 4’-fluoro-2’-metilo como inhibidores de la replicación de hcv arn
BR112015031763A2 (pt) Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
PH12022553530A1 (en) 1'-cyano nucleoside analogs and uses thereof
MX2021005087A (es) Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae.
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
AR081261A1 (es) Metodos para tratar afecciones virales
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
ECSP15015737A (es) Análogos de 2'-cloro nucleósido para infección por vhc
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
EA026341B9 (ru) Кристаллическая форма нуклеозидфосфорамидата
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
MY190867A (en) ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
BR112012014729A2 (pt) terapia combinada contra hcv
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
BR112015023017A2 (pt) combinação de dois antivirais para o tratamento de hepatite c
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX389088B (es) Métodos para tratar el vhc.
EA201692065A1 (ru) Применение 1,3,5-триазин-2-ил фосфорамидатного соединения в синтезе софосбувира
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.

Legal Events

Date Code Title Description
FB Suspension of granting procedure